ライフサイエンスコーパス: be experienced by

1 very 700 births; major obstetric haemorrhage is experienced by 1 in 172 women; cases of eclampsia hav

2 AMPT-induced return of depressive symptoms was experienced by 11 of the 18 patients and led to decr

3 Severe exacerbations were experienced by 11% of the patients in IRF groups an

4 98], P = .03).Persistent mobility disability was experienced by 120 participants (14.7%) in the physi

5 At least one privation was experienced by 18% of the sample; blacks (OR, 2.6; P

6 Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5;

7 Early ICU readmission and death was experienced by 2.54% and 0.92% of all patients, resp

8 (first HF-related hospitalization or death) was experienced by 22 (24%) in the intervention group an

9 Grade 4 thrombocytopenia was experienced by 22.1% of patients in 5.1% of courses.

10 Clinical benefit response was experienced by 23.8% of gemcitabine-treated patients

11 ong 5269 participants, cardiovascular events were experienced by 251 (8.9%) of 2823 patients taking a

12 its; however, mild sensory symptoms or signs were experienced by 27 patients; 'prickling' or 'asleep

13 Grade 3 or 4 anemia was experienced by 29.2% of patients in 8.5% of courses.

14 Excluding pouchitis, late complications were experienced by 29.1% of patients.

15 t least one treatment-emergent adverse event was experienced by 30-36% of participants in each group.

16 Serious or life-threatening toxicity was experienced by 34%, with asthenia (15%) and neuropsy

17 Negative discrimination was experienced by 344 (47%) of 729 participants in maki

18 Serious adverse events were experienced by 35 (18%) patients in the olaparib gr

19 Chronic severe pain was experienced by 37% of MMTP patients (95% confidence

20 associated treatment-limiting adverse events were experienced by 41% of the patients.

21 'Worry about falling' was experienced by 42.0% (128/305) of fallers, 'loss of

22 Grade 3/4 adverse events were experienced by 43% of patients.

23 azithromycin group, 473; placebo group, 464) were experienced by 443 children (azithromycin group, 22

24 Adverse events were experienced by 46 (57%) of 81 patients in the ALD40

25 Nausea and vomiting were experienced by 47.0% of all physostigmine-treated s

26 neutropenia, thrombocytopenia, and mucositis were experienced by 48 (92%), 46 (88%), and 10 (19%) pat

27 Grade 4 neutropenia was experienced by 50.4% of patients in 13.4% of courses

28 Hundred erosions were experienced by 85 patients (2.85%) at a median time

29 On-study SREs were experienced by 9% of denosumab-treated patients (20

30 Continued long-term immunologic benefit may be experienced by a subset of children, despite only tra

31 (13.3%), conversion (2.2%), and leaks (5.8%) were experienced by a total of 22 patients (18.3%).

32 se rapidly, such that the same concentration is experienced by all bacteria.

33 elevations in plasma CORT levels (eg, as may be experienced by an individual during stressful episode

34 Further, these data suggest that haem stress is experienced by bacterial pathogens during infection.

35 oxicities (gastrointestinal events and rash) were experienced by four patients.

36 the intensity of one kind of selection that is experienced by genes and can be used to assess the im

37 ber pressures, and tissue strains that could be experienced by implanted cardiac tissues.

38 Instead, gravitational forces may be experienced by individual cells in the living organis

39 lifelong impairment in face recognition that is experienced by individuals who suffer from congenital

40 Although pain is experienced by many patients with diabetic neuropathy

41 e demonstrate that these metabolic pressures are experienced by Mtb inside its host macrophage and th

42 Smaller losses were experienced by non-children's hospital teaching hos

43 dverse event was minor ear infections, which was experienced by one patient in the gentamicin group a

44 ty reduction has occurred since 1900 and has been experienced by only about 4 of the roughly 8,000 hu

45 lation, the growth benefit from phycospheres is experienced by only a small fraction of cells.

46 ithout the radical evolutionary changes that are experienced by other species, suggesting that specie

47 addition, the poor physical functioning that is experienced by patients who are on dialysis is potent

48 Stable disease was experienced by seven patients for 11 to 18 weeks.

49 opportunities to achieve optimal health that are experienced by socially disadvantaged population gro

50 shows acute muscle wasting and weakness and is experienced by some patients with severe systemic ill

51 y a motivational role, however, they need to be experienced by the organism.

52 atial locations where the perturbations have been experienced by the moving arm.

53 Adverse events were experienced by the majority of patients, but estima

54 esthesia for either treatment, although pain was experienced by these patients in 46.8% of the contro

55 icity was enhanced at cool temperatures that are experienced by this organism in its natural habitat.

56 important reduction in hospitalization rates is experienced by transplanted patients.